Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities
Net loss	$ (103,358)	$ (19,377)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property and equipment	67	114
Amortization of platform development and intangible assets	4,870	7,021
Amortization of debt discounts	536	930
Noncash and accrued interest	2,839
Loss on impairment of assets	40,589	119
Change in fair value of contingent consideration	313	499
Liquidated damages	76	127
Stock-based compensation	1,451	6,427
Deferred income taxes	31	7
Bad debt expense	670	36
Change in operating assets and liabilities net of effect of business combination:
Accounts receivable, net	12,029	10,303
Subscription acquisition costs	6,131	(4,304)
Prepayments and other current assets	(424)	(7,596)
Other long-term assets	(148)	61
Accounts payable	(102)	2,595
Accrued expenses and other	44,334	(2,144)
Unearned revenue	(11,665)	3,464
Subscription refund liability	18	95
Operating lease liabilities	(60)	(56)
Other long-term liabilities	(162)	7
Net cash used in operating activities	(1,965)	(1,672)
Cash flows from investing activities
Capitalized platform development	(713)	(1,188)
Payments for acquisition of business, net of cash acquired		(500)
Net cash used in investing activities	(713)	(1,688)
Cash flows from financing activities
Payment of Fexy put option	(2,263)
Proceeds (repayments) under line of credit, net borrowing	(19,609)	(4,533)
Proceeds from common stock private placement	12,000
Proceeds from Simplify loan	7,748
Proceeds from common stock registered direct offering		11,500
Payments of issuance costs from common stock registered direct offering		(69)
Payment of deferred cash payments		(25)
Payment of taxes from common stock withheld	(479)	(1,423)
Net cash (used in) provided by financing activities	(2,603)	5,450
Net increase (decrease) in cash, cash equivalents, and restricted cash	(5,281)	2,090
Cash, cash equivalents, and restricted cash – beginning of period	9,284	14,373
Cash, cash equivalents, and restricted cash – end of period	4,003	16,463
Cash, cash equivalents, and restricted cash
Cash and cash equivalents	4,003	15,961
Restricted cash		502
Total cash, cash equivalents, and restricted cash	4,003	16,463
Supplemental disclosure of cash flow information
Cash paid for interest	964	3,252
Cash paid for income taxes	85
Noncash investing and financing activities
Reclassification of stock-based compensation to platform development	208	307
Issuance cost of registered direct offering recorded in accrued expenses and other		220
Repurchase of common stock for Fexy put option	379
Issuance of common stock in connection with settlement of liquidated damages		370
Issuance of common stock in connection with acquisition		2,000
Deferred cash payments recorded in connection with acquisitions		246
Reclassification to liability upon common stock modification		$ 68